Novartis wins EU approval for Cosentyx in polymyalgia rheumatica

• European Commission clears Novartis’ Cosentyx for adults with polymyalgia rheumatica inadequately controlled by glucocorticoids or relapsing during tapering.
• Phase III REPLENISH trial showed Cosentyx doubled sustained remission rates versus placebo at Week 52.
• Regulatory reviews for the indication remain ongoing globally, including in the US and Japan.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novartis AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610211100OMX_____CNEWS_EN_GNW1001279159_en) on October 21, 2026, and is solely responsible for the information contained therein.